Keywords: Shire, Acceleron, Rare diseases, Licensing, Duchenne muscular dystrophy

Shire to pay nearly $500 million to expand rare diseases pipeline in deal with Acceleron Pharma

Article | 10 September 2010

Ireland-headquartered drugmaker Shire (LSE: SHP) plans to expand its human genetic therapies pipeline through an exclusive license, in markets outside ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Shire

Acceleron Pharma

Go to company listing